Post-ERCP Acute Pancreatitis Clinical Trial
Official title:
A Prospective, Open Label Randomized Controlled Trial of Prophylactic Rectal Indomethacin Versus Combined Pancreatic Duct Stent Placement and Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care. If there is a comparison group: Researchers will compare [rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.] to see if [whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis].
Status | Recruiting |
Enrollment | 384 |
Est. completion date | May 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Suspected sphincter of Oddi dysfunction 2. History of post ERCP Pancreatitis 3. Pancreatic instrumentation or sphincterotomy. 4. Precut sphincteroyomy 5. Difficult cannulation defined by more than 5 cannulation attempts 6. The use of double wire technique in bile duct access 7. At least 2 of the followings including 1. Female age < 50 year 2. 3 pancreatogram 3. Acinarization (Contrast injection to tail of pancreas 4. Normal serum bilirubin 5. Guidewire to the tail of pancreas or secondary branches Exclusion Criteria: 1. Patient planned for pancreatic stenting 2. Without informed consent 3. Age < 18 years 4. Pregnant women 5. Lactating women 6. Patient with altered anatomy 7. Contraindications to the use of NSAIDS 8. Renal failure 9. Ongoing or recent hospitalisation for acute pancreatitis 10. Allergy to aspirin or NSAIDs 11. known chronic calcific pancreatitis - |
Country | Name | City | State |
---|---|---|---|
India | Department of Gastroenterology and Hepatology | Allahabad | Uttar Pradesh |
India | Department of Gastroenterology and Hepatology, MLN Medical college and SRN Hospital | Allahabad | Uttar Pradesh |
Lead Sponsor | Collaborator |
---|---|
Moti Lal Nehru Medical College |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To compare rectal indomethacin alone versus combined pancreatic duct stent and rectal indomethacin in prevention of post ERCP pancreatitis | For comparison between these two arms the investigators will measure serum amylase in U/L value after 6 hour and 24 hour of the ERCP procedure. The investigators will also assess for pain abdomen and vomiting suggestive of acute pancreatitis. | 24 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546867 -
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
|
N/A | |
Terminated |
NCT02241512 -
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
|
Phase 2 | |
Completed |
NCT00222092 -
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
|
Phase 4 | |
Completed |
NCT05310409 -
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
|
||
Not yet recruiting |
NCT06260878 -
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT04770857 -
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
|
||
Completed |
NCT02641561 -
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
|
Phase 3 | |
Active, not recruiting |
NCT04145336 -
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
|
N/A | |
Completed |
NCT03629600 -
Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03756116 -
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
|
N/A | |
Recruiting |
NCT05664074 -
Rectal Indomethacin vs Intravenous Ketorolac
|
Phase 4 | |
Completed |
NCT02308891 -
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05336630 -
Study of Forceps Cannulation During ERCP
|
N/A | |
Recruiting |
NCT05267379 -
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
|
||
Recruiting |
NCT05947461 -
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
|
N/A | |
Completed |
NCT03098082 -
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT02839356 -
Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Recruiting |
NCT02830984 -
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
|
N/A | |
Completed |
NCT01673763 -
Post-ERCP Pancreatitis Prevention by Stent Insertion
|
N/A | |
Active, not recruiting |
NCT04425993 -
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention
|
N/A |